Journal
CARDIOVASCULAR DIABETOLOGY
Volume 16, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s12933-017-0571-1
Keywords
Acute coronary syndrome; Glucose fluctuation; Heart rate variability; Hypoglycemia; Miglitol; Sympathetic nervous system activity; Type 2 diabetes
Funding
- Astellas
- Takeda
- Daiichi Sankyo
- MSD
- Novartis
- Boehringer Ingelheim
- AstraZeneca
- Pfizer
- Taisho Toayama
- Ono
- Kowa
- Arkray Marketing
- Kissei
- Mitsubishi Tanabe
- Bayer
- Astra Zeneka
- Abbott Vascular
- Boston Scientific
- Sanofi
- MID
- Goodman
- Sanwa Kagaku Kenkyusho
- Teijin
- Grants-in-Aid for Scientific Research [16H05299, 16K01823] Funding Source: KAKEN
Ask authors/readers for more resources
Background: Little is known about clinical associations between glucose fluctuations including hypoglycemia, heart rate variability (HRV), and the activity of the sympathetic nervous system (SNS) in patients with acute phase of acute coronary syndrome (ACS). This pilot study aimed to evaluate the short-term effects of glucose fluctuations on HRV and SNS activity in type 2 diabetes mellitus (T2DM) patients with recent ACS. We also examined the effect of suppressing glucose fluctuations with miglitol on these variables. Methods: This prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group comparative study included 39 T2DM patients with recent ACS, who were randomly assigned to either a miglitol group (n = 19) or a control group (n = 20). After initial 24-h Holter electrocardiogram (ECG) (Day 1), miglitol was commenced and another 24-h Holter ECG (Day 2) was recorded. In addition, continuous glucose monitoring (CGM) was performed throughout the Holter ECG. Results: Although frequent episodes of subclinical hypoglycemia (=4.44 mmo/L) during CGM were observed on Day 1 in the both groups (35% of patients in the control group and 31% in the miglitol group), glucose fluctuations were decreased and the minimum glucose level was increased with substantial reduction in the episodes of subclinical hypoglycemia to 7.7% in the miglitol group on Day 2. Holter ECG showed that the mean and maximum heart rate and mean LF/HF were increased on Day 2 in the control group, and these increases were attenuated by miglitol. When divided 24-h time periods into day-time (0700-1800 h), night-time (1800-0000 h), and bed-time (0000-0700 h), we found increased SNS activity during day-time, increased maximum heart rate during night-time, and glucose fluctuations during bed-time, which were attenuated by miglitol treatment. Conclusions: In T2DM patients with recent ACS, glucose fluctuations with subclinical hypoglycemia were associated with alterations of HRV and SNS activity, which were mitigated by miglitol, suggesting that these pathological relationships may be a residual therapeutic target in such patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available